Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: a bedside-to-bench approach
| العنوان: | Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: a bedside-to-bench approach |
|---|---|
| المؤلفون: | Rasmus R. Mikkelsen, Malthe P. Hundahl, Christopher K. Torp, Javier Rodríguez-Carrio, Mads Kjolby, Jens M. Bruun, Tue W. Kragstrup |
| المصدر: | Scopus Mikkelsen, R R, Hundahl, M P, Torp, C K, Rodríguez-Carrio, J, Kjolby, M, Bruun, J M & Kragstrup, T W 2022, ' Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus : A bedside-to-bench approach ', European Journal of Pharmacology, vol. 925, 174998 . https://doi.org/10.1016/j.ejphar.2022.174998Test |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Inflammation/chemically induced, Methotrexate/therapeutic use, Sulfasalazine/therapeutic use, Interleukin-1beta, Antibodies, Monoclonal, Humanized, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Etanercept, Immunomodulating Agents, Animals, Humans, Immunosuppression Therapy, Inflammation, Pharmacology, Diabetes Mellitus, Type 2/complications, Etanercept/pharmacology, Sulfasalazine, Interleukin 1 Receptor Antagonist Protein, Methotrexate, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Hydroxychloroquine/therapeutic use, Cardiovascular Diseases/drug therapy, Colchicine, Immunosuppressive Agents, Hydroxychloroquine, Interleukin-1 |
| الوصف: | OBJECTIVE: To assess which immunosuppressive drugs have been investigated and proven efficacious in patients with cardiovascular disease (CVD) or type 2 diabetes (T2D) without preexisting immune mediated disorders to validate in vitro and animal model findings on low grade inflammation (bedside-to-bench).METHODS: Clinical trials on immunosuppressive drugs in CVD or T2D were found in PubMed. Studies on patients with preexisting immune mediated inflammatory disease were excluded. A total of 19 clinical trials testing canakinumab, anakinra, methotrexate, colchicine, hydroxychloroquine, etanercept and sulfasalazine were found.RESULTS: Canakinumab and colchicine significantly reduced the risk of CVD, whereas methotrexate did not. Sulfasalazine showed no effect on vascular function. Anakinra and hydroxychloroquine had a positive effect on glycemic control and β-cell function in T2D. Etanercept had no effect in patients with T2D.CONCLUSION: The observed results indicate that immunosuppressive drugs specifically targeting IL-1β hold promise for dampening CVD and T2D. These findings validate in vitro and animal models showing involvement of the IL-1-axis in the pathogenesis of CVD and T2D. The use of immunosuppressive drugs targeting the chronic inflammation in these diseases could be a possible future treatment strategy as an add-on to the existing pharmacological treatment of CVD and T2D. However, potential treatment effects, adverse events and cost-effectiveness should be carefully considered with importance for drug development. |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f756fa0c7d520da4cd8a98288ea820dTest http://hdl.handle.net/10651/65535Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3f756fa0c7d520da4cd8a98288ea820d |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |